Zynerba Pharmaceuticals Is A Biopharmaceutical Company Focused On Developing Therapies For Rare Neuropsychiatric Conditionsthe Company Specializes In Transdermal Cannabinoid Delivery Systemsaiming To Meet The Medical Needs Of Patients With Disorders Such As Fragile X Syndrome And 22Q11 2 Deletion Syndromein 2023Zynerba Was Acquired By Harmony Biosciencesenhancing Its Capabilities And Resources The Company S Lead Productzygelis A Synthetic Cannabidiolcbdformulated As A Transdermal Gelthis Innovative Delivery System Allows For Consistent Cannabinoid Absorption Through The Skinimproving Safety And Efficacy By Bypassing Gastrointestinal Metabolismzynerba S Clinical Pipeline Includes Zygelwhich Is Currently Undergoing Phase 3 Trials For Fragile X Syndrome And Phase 2 Trials For 22Q11 2 Deletion Syndromezynerba Is Dedicated To Improving The Quality Of Life For Patients And Families Affected By These Challenging Conditions
No conferences found for this company.
| Company Name | Zynerba Pharmaceuticals Pty Ltd |
| Country |
Australia
|
| Address | N/A |
| Telephone | N/A |
| N/A |
